Advertisement

New Approaches to Diagnosis and Treatment of Functional Dyspepsia

  • Toshihiko Tomita
  • Tadayuki Oshima
  • Hiroto MiwaEmail author
Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract

Abstract

Purpose of Review

The purpose of this article is to review the recent literature and discuss the new approaches to the diagnosis and treatment of functional dyspepsia (FD).

Recent Findings

According to the recent American College of Gastroenterology (ACG) and Canadian Association of Gastroenterology (CAG) guideline for dyspepsia, Helicobacter pylori (H. pylori) eradication is recommended as a first treatment option, and proton pump inhibitors (PPIs), tricyclic antidepressants, and prokinetics are listed as second-line therapy. On the other hand, in the Japanese guideline for FD, PPIs and prokinetics are recommended as the first-line treatment. In Japan, acotiamide, a recently launched prokinetic, showed significant efficacy in several clinical trials performed either in Japan or Europe. Regarding non-pharmacological treatment, recent topics include acupuncture, electrical stimulation, gastric peroral endoscopic myotomy, and meal and lifestyle modification. These treatments have provided significant efficacy, which provides some insights into the main pathophysiology of this disease.

Summary

Although FD is common among functional gastrointestinal disorders, it is not easy to relieve the dyspeptic symptoms of FD patients. Combinations of pharmacological and non-pharmacological treatment options are expected.

Keywords

Functional dyspepsia (FD) Diagnosis Treatment Proton pump inhibitor (PPI) Acotiamide Tricyclic antidepressant (TCA) 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the author.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92 This paper is an updated Rome classification of FD. CrossRefGoogle Scholar
  2. 2.
    Miwa H, Kusano M, Arisawa T, Oshima T, Kato M, Joh T, et al. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol. 2015;50(2):125–39.CrossRefGoogle Scholar
  3. 3.
    Oshima T, Miwa H. Epidemiology of functional gastrointestinal disorders in Japan and in the world. J Neurogastroenterol Motil. 2015;21(3):320–9.CrossRefGoogle Scholar
  4. 4.
    •• Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112(7):988–1013 This paper is an updated ACG and CAG guidelines of FD.CrossRefGoogle Scholar
  5. 5.
    Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466–79 Review.CrossRefGoogle Scholar
  6. 6.
    Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004. 1490;328(7454):19.Google Scholar
  7. 7.
    Vanheel H, Carbone F, Valvekens L, et al. Pathophysiological abnormalities in functional dyspepsia subgroups according to the Rome III criteria. Am J Gastroenterol. 2017;112:132140.CrossRefGoogle Scholar
  8. 8.
    Asano H, Tomita T, Nakamura K, Yamasaki T, Okugawa T, Kondo T, et al. Prevalence of gastric motility disorders in patients with functional dyspepsia. J Neurogastroenterol Motil. 2017;23(3):392–9.CrossRefGoogle Scholar
  9. 9.
    DiBaise JK, Patel N, Noelting J, Dueck AC, Roarke M, Crowell MD. The relationship among gastroparetic symptoms, quality of life, and gastric emptying in patients referred for gastric emptying testing. Neurogastroenterol Motil. 2016;28:234–42.CrossRefGoogle Scholar
  10. 10.
    Simrén M, Törnblom H, Palsson OS, van Tilburg MAL, Van Oudenhove L, Tack J, et al. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. Gut. 2018;67(2):255–62.CrossRefGoogle Scholar
  11. 11.
    • Carbone F, Tack J, Hoffman I. The intragastric pressure measurement: a novel method to assess gastric accommodation in functional dyspepsia children. J Pediatr Gastroenterol Nutr. 2017;64(6):918–24 This paper showed new measurement methods of adaptive relaxation response of the stomach using high-resolution manometry. CrossRefGoogle Scholar
  12. 12.
    Carbone F, Vanuytsel T, Tack J. The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects. Neurogastroenterol Motil 2017;29(12).Google Scholar
  13. 13.
    Wu Q, Zou M, Yang M, Zhou S, Yan X, Sun B, et al. Revealing potential biomarkers of functional dyspepsia by combining 1H NMR metabonomics techniques and an integrative multi-objective optimization method. Sci Rep. 2016;6:18852.CrossRefGoogle Scholar
  14. 14.
    Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on “Helicobacter pylori eradication in functional dyspepsia”. Arch Intern Med. 2011;171(21):1936–7.CrossRefGoogle Scholar
  15. 15.
    Mazzoleni LE, Sander GB, Francesconi CF, Mazzoleni F, Uchoa DM, De Bona LR, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011;28;171(21):1929–1936.Google Scholar
  16. 16.
    Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67.CrossRefGoogle Scholar
  17. 17.
    • Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017; This paper is a systematic review to evaluate whether PPI therapy provides symptomatic relief in FD. Google Scholar
  18. 18.
    Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007;5(2):178–85.CrossRefGoogle Scholar
  19. 19.
    Lee KJ, Demarchi B, Demedts I, Sifrim D, Raeymaekers P, Tack J. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 2004;99(9):1765–73.CrossRefGoogle Scholar
  20. 20.
    Oshima T, Okugawa T, Tomita T, Sakurai J, Toyoshima F, Watari J, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. Aliment Pharmacol Ther. 2012;35(1):175–82.CrossRefGoogle Scholar
  21. 21.
    Ishii M, Kusunoki H, Manabe N, Kamada T, Sato M, Imamura H, et al. Evaluation of duodenal hypersensitivity induced by duodenal acidification using transnasal endoscopy. J Gastroenterol Hepatol. 2010;25(5):913–8.CrossRefGoogle Scholar
  22. 22.
    NJ WMM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:11751183.Google Scholar
  23. 23.
    Wang X, Li X, Ge W, Huang J, Li G, Cong Y, et al. Quantitative evaluation of duodenal eosinophils and mast cells in adult patients with functional dyspepsia. Ann Diagn Pathol. 2015;19(2):50–6.CrossRefGoogle Scholar
  24. 24.
    Du L, Shen J, Kim JJ, Yu Y, Ma L, Dai N. Increased duodenal eosinophil degranulation in patients with functional dyspepsia: a prospective study. Sci Rep. 2016;6:34305.CrossRefGoogle Scholar
  25. 25.
    Potter MDE, Wood NK, Walker MM, Jones MP, Talley NJ. Proton pump inhibitors and suppression of duodenal eosinophilia in functional dyspepsia. Gut. 2018.Google Scholar
  26. 26.
    Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821–8.CrossRefGoogle Scholar
  27. 27.
    Altan E, Masaoka T, Farré R, Tack J. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome. Expert Rev Gastroenterol Hepatol. 2012;6(5):533–44.CrossRefGoogle Scholar
  28. 28.
    Nakamura K, Tomita T, Oshima T, Asano H, Yamasaki T, Okugawa T, et al. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia. J Gastroenterol. 2017;52(5):602–10.CrossRefGoogle Scholar
  29. 29.
    •• Tack J, Pokrotnieks J, Urbonas G, Banciu C, Yakusevich V, Bunganic I, et al. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial. Neurogastroenterol Motil. 2018;30(6):e13284 This paper indicated the long-term safety and efficacy of acotiamide in FD. CrossRefGoogle Scholar
  30. 30.
    Yamawaki H, Futagami S, Kawagoe T, Maruki Y, Hashimoto S, Nagoya H, et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037–47.CrossRefGoogle Scholar
  31. 31.
    • Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66(3):411–420. Review This paper is a systematic review of psychotropic drug in FD. CrossRefGoogle Scholar
  32. 32.
    Braak B, Klooker TK, Wouters MM, Lei A, van den Wijngaard RM, Boeckxstaens GE. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlledstudy. Aliment Pharmacol Ther. 2011 Sep;34(6):638–48.CrossRefGoogle Scholar
  33. 33.
    Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015 Aug;149(2):340–9.e2.CrossRefGoogle Scholar
  34. 34.
    Tan VP, Cheung TK, Wong WM, Pang R, Wong BC. Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study. World J Gastroenterol. 2012;18(42):6127–33.CrossRefGoogle Scholar
  35. 35.
    • Tominaga K, Sakata Y, Kusunoki H, Odaka T, Sakurai K, Kawamura O, et al. Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: a randomized clinical trial (the DREAM study). Neurogastroenterol Motil. 2018;30(7):e13319 This paper is a randomized, placebo-controlled, double-blind clinical trial to determine the efficacy of rikkunshito in FD patients. CrossRefGoogle Scholar
  36. 36.
    Suzuki H, Matsuzaki J, Fukushima Y, Suzaki F, Kasugai K, Nishizawa T, et al. Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil. 2014;26(7):950–61.CrossRefGoogle Scholar
  37. 37.
    Kim KN, Chung SY, Cho SH. Efficacy of acupuncture treatment for functional dyspepsia: a systematic review and meta-analysis. Complement Ther Med. 2015;23(6):759–66.CrossRefGoogle Scholar
  38. 38.
    Lan L, Zeng F, Liu GJ, Ying L, Wu X, Liu M, et al. Acupuncture for functional dyspepsia. Cochrane Database Syst Rev. 2014;10:CD008487.Google Scholar
  39. 39.
    Zheng H, Xu J, Sun X, Zeng F, Li Y, Wu X, et al. Electroacupuncture for patients with refractory functional dyspepsia: a randomized controlled trial. Neurogastroenterol Motil. 2018;30(7):e13316.CrossRefGoogle Scholar
  40. 40.
    Laine M, Sirén J, Koskenpato J, Punkkinen J, Rantanen T, Typpö I, et al. Outcomes of high-frequency gastric electric stimulation for the treatment of severe, medically refractory gastroparesis in Finland. Scand J Surg. 2018;107(2):124–9.CrossRefGoogle Scholar
  41. 41.
    Davis BR, Sarosiek I, Bashashati M, Alvarado B, McCallum RW. The long-term efficacy and safety of pyloroplasty combined with gastric electrical stimulation therapy in gastroparesis. J Gastrointest Surg. 2017;21(2):222–7.CrossRefGoogle Scholar
  42. 42.
    Mekaroonkamol P, Dacha S, Wang L, Li X, Jiang Y, Li L, et al. Gastric peroral endoscopic pyloromyotomy reduces symptoms, increases quality of life, and reduces health care use for patients with gastroparesis. Clin Gastroenterol Hepatol 2018Google Scholar
  43. 43.
    Xue HB, Fan HZ, Meng XM, Cristofaro S, Mekaroonkamol P, Dacha S, et al. Fluoroscopy-guided gastric peroral endoscopic pyloromyotomy (G-POEM): a more reliable and efficient method for treatment of refractory gastroparesis. Surg Endosc. 2017;31(11):4617–24.CrossRefGoogle Scholar
  44. 44.
    Malik Z, Kataria R, Modayil R, Ehrlich AC, Schey R, Parkman HP, et al. Gastric per oral endoscopic myotomy (G-POEM) for the treatment of refractory gastroparesis: early experience. Dig Dis Sci 2018 22.Google Scholar
  45. 45.
    Duncanson KR, Talley NJ, Walker MM, Burrows TL. Food and functional dyspepsia: a systematic review. J Hum Nutr Diet. 2018;31(3):390–407.CrossRefGoogle Scholar
  46. 46.
    Acker BW, Cash BD. Medicinal foods for functional GI disorders. Curr Gastroenterol Rep. 2017;19(12):62.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Toshihiko Tomita
    • 1
  • Tadayuki Oshima
    • 1
  • Hiroto Miwa
    • 1
    Email author
  1. 1.Division of Gastroenterology, Department of Internal MedicineHyogo College of MedicineNishinomiyaJapan

Personalised recommendations